Remicade and Joint lock - a phase IV clinical study of FDA data

Summary:

Joint lock is reported as a side effect among people who take Remicade (infliximab), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Humira, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Joint lock when taking Remicade. It is created by eHealthMe based on reports of 222,651 people who have side effects when taking Remicade from the FDA, and is updated regularly.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 224,011 Remicade users. Check the latest studies of Remicade.

What is Joint lock?

Joint lock is found to be associated with 300 drugs and 491 conditions by eHealthMe. Check the latest studies of Joint lock.

On Jul, 17, 2026

222,651 people reported to have side effects when taking Remicade.
Among them, 208 people (0.09%) have Joint lock.

Among these 208 people:

* Approximation only. Some reports may have incomplete information.

Do you take Remicade and have Joint lock?

- Check whether Joint lock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remicade:

Remicade (224,011 reports)

Joint lock treatments and more:

Joint lock (3,416 reports)

How severe was Joint lock and when was it recovered:

Joint lock in Remicade

Expand to all the drugs that have ingredients of infliximab:

Joint lock and drugs with ingredients of infliximab (218 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Remicade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint lock:

Joint lock (300 drugs)

Browse all the conditions that are associated with Joint lock:

Joint lock (491 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab (the active ingredients of Remicade) and Remicade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.